Objective To evaluate the efficacy and toxicities of pemetrexed as second-line treatment of elderly patients with advanced non-small cell lung cancer. Methods Thirty elderly patients with advanced non-small cell lung cancer were treated with pemetrexed 500 mg/m2 on day1. The chemotherpy repeated every 3 weeks. Efficacy and toxicities were reviewed after at least 2 cycles of chemotherapy. Results All the patients could be included for response rate and the overall response rate was 13.3％( 4/30 ) with 0 case of complete response( CR ) and 4 of partial response ( PR ),14 of steadiness( SD ) and 12 of progressive disease ( PD ). The clinical benefit rate was 60.0％( 18/30 ). Median time to progress ( TTP ) was 3.1 months, median survival time ( MST )was 7.5 months. The main adverse reactions were myelosuppression. Conclusion Pemetrexed is well tolerated and effecitive as second-line treatment of elderly patients with advanced non-small cell lung cancer.%目的 评价培美曲塞二线治疗老年晚期非小细胞肺癌的疗效和不良反应.方法 30例老年晚期非小细胞肺癌患者接受培美曲塞500 mg/m2静脉滴注,第1天;3周为1个周期.至少2个周期后评价疗效及不良反应.结果 可评价疗效者30例,治疗后获得完全缓解(CR)0例,部分缓解(PR)4例,稳定(SD)14例,进展(PD)12例,总有效率(RR)为13.3%(4/30).临床获益率为60.0%(18/30).中位疾病进展时间(TTP)为3.1个月,中位生存期(MST)为7.5个月.主要不良反应为骨髓抑制.结论 培美曲塞二线治疗老年晚期非小细胞肺癌疗效肯定,且不良反应可耐受.
展开▼
